CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
TSX:CPH • CA17253X1050
15.01 CAD
-0.19 (-1.25%)
Last: Feb 27, 2026, 07:00 PM
CPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. CPH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPH is growing strongly while it is still valued neutral. This is a good combination! These ratings could make CPH a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- CPH had positive earnings in the past year.
- In the past year CPH had a positive cash flow from operations.
- In the past 5 years CPH has always been profitable.
- CPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 11.77%, CPH belongs to the best of the industry, outperforming 91.18% of the companies in the same industry.
- With an excellent Return On Equity value of 15.23%, CPH belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
- The Return On Invested Capital of CPH (7.23%) is better than 88.24% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 8.25%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
- Looking at the Profit Margin, with a value of 34.68%, CPH belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- CPH's Profit Margin has improved in the last couple of years.
- CPH's Operating Margin of 25.51% is amongst the best of the industry. CPH outperforms 85.29% of its industry peers.
- In the last couple of years the Operating Margin of CPH has declined.
- The Gross Margin of CPH (74.32%) is better than 94.12% of its industry peers.
- CPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
- CPH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for CPH has been increased compared to 1 year ago.
- CPH has less shares outstanding than it did 5 years ago.
- CPH has a worse debt/assets ratio than last year.
2.2 Solvency
- CPH has an Altman-Z score of 6.47. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
- CPH has a better Altman-Z score (6.47) than 94.12% of its industry peers.
- CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
- The Debt to FCF ratio of CPH (0.45) is better than 94.12% of its industry peers.
- A Debt/Equity ratio of 0.12 indicates that CPH is not too dependend on debt financing.
- CPH has a better Debt to Equity ratio (0.12) than 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.47 |
ROIC/WACC0.86
WACC8.46%
2.3 Liquidity
- CPH has a Current Ratio of 1.30. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.30, CPH is not doing good in the industry: 67.65% of the companies in the same industry are doing better.
- A Quick Ratio of 0.98 indicates that CPH may have some problems paying its short term obligations.
- CPH has a Quick ratio of 0.98. This is comparable to the rest of the industry: CPH outperforms 41.18% of its industry peers.
- CPH does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 4.76% over the past year.
- Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.97% on average per year.
- The Revenue has grown by 89.17% in the past year. This is a very strong growth!
- CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
- The Earnings Per Share is expected to grow by 20.66% on average over the next years. This is a very strong growth
- CPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.91% yearly.
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year51.28%
Revenue Next 2Y24.88%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 16.68 indicates a correct valuation of CPH.
- Based on the Price/Earnings ratio, CPH is valued a bit cheaper than the industry average as 79.41% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 27.07, CPH is valued a bit cheaper.
- CPH is valuated quite expensively with a Price/Forward Earnings ratio of 27.87.
- CPH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CPH is cheaper than 61.76% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.05. CPH is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.68 | ||
| Fwd PE | 27.87 |
4.2 Price Multiples
- CPH's Enterprise Value to EBITDA is on the same level as the industry average.
- Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than 76.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.28 | ||
| EV/EBITDA | 14.34 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- CPH has an outstanding profitability rating, which may justify a higher PE ratio.
- CPH's earnings are expected to grow with 20.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.32
PEG (5Y)1.29
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
- CPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (2/27/2026, 7:00:00 PM)
15.01
-0.19 (-1.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-12 2026-03-12
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap379.45M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts80
Price Target19.58 (30.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0%
PT rev (3m)6.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)10.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)-2.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.68 | ||
| Fwd PE | 27.87 | ||
| P/S | 5.54 | ||
| P/FCF | 9.28 | ||
| P/OCF | 9.25 | ||
| P/B | 2.44 | ||
| P/tB | 12.15 | ||
| EV/EBITDA | 14.34 |
EPS(TTM)0.9
EY6%
EPS(NY)0.54
Fwd EY3.59%
FCF(TTM)1.62
FCFY10.78%
OCF(TTM)1.62
OCFY10.81%
SpS2.71
BVpS6.16
TBVpS1.24
PEG (NY)0.32
PEG (5Y)1.29
Graham Number11.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.47 |
F-Score7
WACC8.46%
ROIC/WACC0.86
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year51.28%
Revenue Next 2Y24.88%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year143.79%
EBIT Next 3Y45.72%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status for CPH stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
What is the profitability of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.68 and the Price/Book (PB) ratio is 2.44.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.